Joel D. Parry

596 total citations
12 papers, 275 citations indexed

About

Joel D. Parry is a scholar working on Molecular Biology, Organic Chemistry and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Joel D. Parry has authored 12 papers receiving a total of 275 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Molecular Biology, 2 papers in Organic Chemistry and 2 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Joel D. Parry's work include RNA Interference and Gene Delivery (3 papers), Advanced biosensing and bioanalysis techniques (3 papers) and Bioactive Compounds and Antitumor Agents (2 papers). Joel D. Parry is often cited by papers focused on RNA Interference and Gene Delivery (3 papers), Advanced biosensing and bioanalysis techniques (3 papers) and Bioactive Compounds and Antitumor Agents (2 papers). Joel D. Parry collaborates with scholars based in United Kingdom, United States and Switzerland. Joel D. Parry's co-authors include Timothy W. Gant, Jinli Luo, Jonathan J. Lyon, Amy Pointon, Shudong Zhang, Emma L. Marczylo, Tracy Walker, Joan Riley, Mark R. Edbrooke and Paul A. Wilson and has published in prestigious journals such as Nucleic Acids Research, PLoS ONE and Chemical Research in Toxicology.

In The Last Decade

Joel D. Parry

11 papers receiving 263 citations

Peers

Countries citing papers authored by Joel D. Parry

Since Specialization

Citations

This map shows the geographic impact of Joel D. Parry's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joel D. Parry with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joel D. Parry more than expected).

Fields of papers citing papers by Joel D. Parry

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Joel D. Parry. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joel D. Parry. The network helps show where Joel D. Parry may publish in the future.

Co-authorship network of co-authors of Joel D. Parry

This figure shows the co-authorship network connecting the top 25 collaborators of Joel D. Parry. A scholar is included among the top collaborators of Joel D. Parry based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Joel D. Parry. Joel D. Parry is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

12 of 12 papers shown

#	Work	Indexed citations
1	An Industry Perspective on Key Considerations for the ICH S13 Guidance: Nonclinical Safety Evaluations of Oligonucleotide-Based Therapeutics 2026 ·International Journal of Toxicology ·Jennifer D. Sisler, Patrik Andersson, (unknown), Carole E. Harbison, Onyi Irrechukwu, Helen L. Lightfoot, Michaël Maes, (unknown), Joel D. Parry, Justin D. Schumacher, (unknown), Yi Yang, (unknown)	0
2	Opportunities for More Tailored Approaches to Genotoxicity Testing and Carcinogenicity Strategy for Oligonucleotide Therapeutics: Outcome of an Industry Survey 2025 ·Nucleic Acid Therapeutics ·Joel D. Parry, (unknown), Patrik Andersson, (unknown), (unknown), (unknown), Anthony Lynch, (unknown), Meredith E. Crosby, (unknown), (unknown), Melanie Guérard, Nicole H.P. Cnubben, (unknown), (unknown), Yi Yan Yang	1
3	The Opportunity of Modern High-Toughness Technical Ceramics for Undersea Systems 2021 ·Marine Technology Society Journal ·(unknown), Joel D. Parry	2
4	Outcomes of the European Federation of Pharmaceutical Industries and Associations Oligonucleotide Working Group Survey on Nonclinical Practices and Regulatory Expectations for Therapeutic Oligonucleotide Safety Assessment 2020 ·Nucleic Acid Therapeutics ·(unknown), (unknown), (unknown), Chidozie J. Amuzie, Patrik Andersson, Joel D. Parry, Jonathan G. Moggs, Laurence O. Whiteley	11
5	Strategies for In Vivo Screening and Mitigation of Hepatotoxicity Associated with Antisense Drugs 2017 ·Molecular Therapy — Nucleic Acids ·Piotr J. Kamola, Klio Maratou, Paul A. Wilson, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Aude Roulois, (unknown), (unknown), (unknown), Nigel J. Gooderham, Timothy W. Gant, Kitty Moores, Stephen Hughes, Mark R. Edbrooke, Kenneth L. Clark, Joel D. Parry	37
6	In silicoandin vitroevaluation of exonic and intronic off-target effects form a critical element of therapeutic ASO gapmer optimization 2015 ·Nucleic Acids Research ·Piotr J. Kamola, Jeremy Kitson, (unknown), Klio Maratou, (unknown), Aliza A. Panjwani, (unknown), (unknown), Kitty Moores, Emma Koppe, William E. Wixted, Paul A. Wilson, Nigel J. Gooderham, Timothy W. Gant, Kenneth L. Clark, Stephen Hughes, Mark R. Edbrooke, Joel D. Parry	81
7	Understanding the behavior of nanoparticulate drug delivery systems in vivo: particle disposition patterns, toxicologic implications and effective drug development 2013 ·Toxicology Letters ·Richard Kirsh, (unknown), Joel D. Parry, (unknown), (unknown), Thomas D. Meek	1
8	Clinical Expert Panel on Monitoring Potential Lung Toxicity of Inhaled Oligonucleotides: Consensus Points and Recommendations 2012 ·Nucleic Acid Therapeutics ·Eric W.F.W. Alton, Homer A. Boushey, Holger Garn, Francis H. Green, Michael R. Hodges, Richard J. Martin, Robert Murdoch, Harald Renz, Stephen B. Shrewsbury, Rosanne Séguin, Graham D. Johnson, Joel D. Parry, (unknown), Paolo Renzi, Joy Cavagnaro, Nicoletta Ferrari	16
9	Anti-inflammatory Disease Therapies 2012 ·Toxicologic Pathology ·Sarah Bolton, (unknown), (unknown), Wolfgang Brück, Jeffrey K. Huang, Stefano Pluchino, (unknown), Joel D. Parry, Mary McFarlane, (unknown), Aude Roulois	1
10	Doxorubicin In Vivo Rapidly Alters Expression and Translation of Myocardial Electron Transport Chain Genes, Leads to ATP Loss and Caspase 3 Activation 2010 ·PLoS ONE ·Amy Pointon, Tracy Walker, (unknown), Jinli Luo, Joan Riley, Shudong Zhang, Joel D. Parry, Jonathan J. Lyon, Emma L. Marczylo, Timothy W. Gant	110
11	Two electron reduction of 2,3-dimethoxy-1,4-naphthoquinone metabolism in vivo prevents redox stress but interaction with the electron transport chain may be a mechanism of toxicity 2009 ·Toxicology Letters ·Timothy W. Gant, Ursula Lutz, Joel D. Parry, Amy Pointon, Joanne Charlwood, Friederike Teichert, Toby J. Athersuch, (unknown), Hector C. Keun, Jonathan J. Lyon, Werner K. Lutz	1
12	Pivotal Role for Two Electron Reduction in 2,3-Dimethoxy-1,4-naphthoquinone and 2-Methyl-1,4-naphthoquinone Metabolism and Kinetics in Vivo That Prevents Liver Redox Stress 2009 ·Chemical Research in Toxicology ·Joel D. Parry, Amy Pointon, Ursula Lutz, Friederike Teichert, Joanne Charlwood, (unknown), Toby J. Athersuch, Emma Taylor, Rajinder Singh, Jinli Luo, (unknown), Angélique Vétillard, Jonathan J. Lyon, Hector C. Keun, Werner K. Lutz, Timothy W. Gant	14

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact